Acrux (ASX:ACR) Other Gross PPE : A$0.00 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Acrux Other Gross PPE?

Acrux's Other Gross PPE for the quarter that ended in Dec. 2024 was A$0.00 Mil.

Acrux's quarterly Other Gross PPE increased from Dec. 2023 (A$0.00 Mil) to Jun. 2024 (A$2.97 Mil) but then declined from Jun. 2024 (A$2.97 Mil) to Dec. 2024 (A$0.00 Mil).

Acrux's annual Other Gross PPE increased from Jun. 2022 (A$2.60 Mil) to Jun. 2023 (A$3.00 Mil) but then declined from Jun. 2023 (A$3.00 Mil) to Jun. 2024 (A$2.97 Mil).

Acrux Other Gross PPE Historical Data

The historical data trend for Acrux's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Other Gross PPE Chart

Acrux Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Other Gross PPE

Get a 7-Day Free Trial

3.70

2.60

3.00

2.97

Acrux Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Gross PPE	Get a 7-Day Free Trial															-	3.00	-	2.97	-

Acrux Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Acrux Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003

Website

https://www.acrux.com.au

Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.